Millions of people worldwide suffer from inflammatory diseases, and many are still waiting for effective treatments. A German company, InflaRx, might have one.
Quoting by excerpt Alexander Burik of Labiotech.eu
We spoke to its founder and CEO, Niels Riedemann, to get the whole story about the company’s technology and its recent $106M IPO on NASDAQ. It might be hard to believe, but one of the most serious threats to our health comes from within our own bodies. Inflammatory disease can occur when the body’s immune system starts attacking its own cells or when inflammation in response to an injury spreads across the whole body. This can result in conditions such as asthma, multiple sclerosis, type 1 diabetes and transplant rejections.
The global treatment market for inflammatory diseases is currently dominated by AbbVie’s Humira, the best-selling drug in the world. Humira is used for many inflammatory conditions, ranging from rheumatoid arthritis to psoriasis and Crohn’s disease. But for many other conditions, there is still no effective treatment available. InflaRx, a German company, may have a solution for them.
“It is not our idea to go after diseases where Humira plays a role,” says Niels Riedemann, founder and CEO of InflaRx. “We have a very different mode of action.”
InflaRx’s technology targets a part of the immune system known as the complement system, which helps antibodies and phagocytic cells clear microbes and damaged cells from an organism, and attacks the cell membrane of bacteria. The biotech’s drugs target a protein of the complement system known as C5. Importantly, the drugs target only a specific fragment of the protein that increases inflammation, while leaving intact other beneficial parts of the protein that protect the body from infections.
Tags: Autoinflammatory Diseases Biologicals HUMIRA Inflammatory Disease Treatment